Oncoinvent（7BG）株式概要オンコインベントASAは臨床段階にある会社で、癌に対する放射性医薬品治療法を開発している。 詳細7BG ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間47.7%増加すると予測されています リスク分析German市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( €33M )意味のある収益がありません ( NOK28M )現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見る7BG Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW485,374 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA485,374 investors already sharing narrativesYour Fair Value€Current Price€7.40183.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-199m197m2016201920222025202620282031Revenue NOK 197.3mEarnings NOK 29.3mAdvancedSet Fair ValueView all narrativesOncoinvent ASA 競合他社Cantourage GroupSymbol: XTRA:HIGHMarket cap: €69.3mTFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mMPH Health CareSymbol: DB:93M1Market cap: €106.2mBiofronteraSymbol: XTRA:B8FKMarket cap: €15.6m価格と性能株価の高値、安値、推移の概要Oncoinvent過去の株価現在の株価NOK 7.4052週高値NOK 9.0452週安値NOK 0.0001ベータ01ヶ月の変化60.17%3ヶ月変化69.72%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化41.49%最新ニュースNew Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr58m net loss in 3 years). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (kr28m revenue, or US$2.9m). Market cap is less than US$100m (€26.5m market cap, or US$30.2m).お知らせ • Jun 19Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of RadspherinOncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine.Board Change • May 20No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Mar 20Oncoinvent Secures New Patent Expanding Protection for RadspherinOncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.お知らせ • Feb 18Oncoinvent to Present Positive 24-Month Follow-Up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026Oncoinvent announced that it will present final 24-month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum-sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes. The poster presentation, titled 'Safety and efficacy results from a phase 1 study of intraperitoneal alpha-EMitting radium-224 labelled microparticles after cytoreductive surgery, will share final 24-month data from the Phase 1 study detailing: 21 patients enrolled across dose levels with a favourable safety profile and no dose-limiting toxicities observed; No grade 3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence.お知らせ • Jan 13Oncoinvent ASA Announces Appointment of Ramzi Amri as CEO, Effective January 2026Oncoinvent ASA announced the appointment of Ramzi Amri as the new CEO of the Company as of January 2026.最新情報をもっと見るRecent updatesNew Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr58m net loss in 3 years). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (kr28m revenue, or US$2.9m). Market cap is less than US$100m (€26.5m market cap, or US$30.2m).お知らせ • Jun 19Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of RadspherinOncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine.Board Change • May 20No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Mar 20Oncoinvent Secures New Patent Expanding Protection for RadspherinOncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.お知らせ • Feb 18Oncoinvent to Present Positive 24-Month Follow-Up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026Oncoinvent announced that it will present final 24-month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum-sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes. The poster presentation, titled 'Safety and efficacy results from a phase 1 study of intraperitoneal alpha-EMitting radium-224 labelled microparticles after cytoreductive surgery, will share final 24-month data from the Phase 1 study detailing: 21 patients enrolled across dose levels with a favourable safety profile and no dose-limiting toxicities observed; No grade 3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence.お知らせ • Jan 13Oncoinvent ASA Announces Appointment of Ramzi Amri as CEO, Effective January 2026Oncoinvent ASA announced the appointment of Ramzi Amri as the new CEO of the Company as of January 2026.Board Change • Dec 30No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Dec 03Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million.Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million. Security Name: Shares Security Type: Common Stock Securities Offered: 260,000,000 Price\Range: NOK 0.5 Transaction Features: Rights Offeringお知らせ • Nov 01Oncoinvent ASA Announces CFO Changes, Effective on or Around January 15, 2025Oncoinvent ASA announced the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January. Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as Vice President and Head of Development Strategy & Execution. He brings broad international experience through leadership positions in strategy, operations, and corporate transformation across the life sciences and healthcare industries. Dr. Amri also brings seven years of management consulting experience from McKinsey & Company, advising global pharma and biotech clients, as well as financial institutions and private-equity-backed businesses, on growth, M&A, and organizational transformation. Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He conducted his Ph.D. research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer.株主還元7BGDE PharmaceuticalsDE 市場7D-7.5%-0.6%1.7%1Yn/a44.7%4.1%株主還元を見る業界別リターン: 7BGがGerman Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 7BG German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 7BG's price volatile compared to industry and market?7BG volatility7BG Average Weekly Movement10.4%Pharmaceuticals Industry Average Movement5.8%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: 7BGの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 7BGの 週次ボラティリティ は過去 1 年間で2627%から10%に減少しましたが、依然としてGerman株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a44Oystein Sougwww.oncoinvent.comOncoinvent ASAは臨床段階にある企業で、癌に対する放射性医薬品治療法を開発している。同社の主要製品候補であるRadspherinは、2つの第1/2a相試験と1つの無作為化第2相試験において、腹膜を含む体腔に転移したがんを治療するアルファ線治療候補である。本社はノルウェーのオスロ。もっと見るOncoinvent ASA 基礎のまとめOncoinvent の収益と売上を時価総額と比較するとどうか。7BG 基礎統計学時価総額€33.03m収益（TTM）-€14.12m売上高(TTM)€2.56m12.9xP/Sレシオ-2.3xPER（株価収益率7BG は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7BG 損益計算書（TTM）収益NOK 28.07m売上原価NOK 0売上総利益NOK 28.07mその他の費用NOK 183.14m収益-NOK 155.07m直近の収益報告Dec 31, 2025次回決算日Aug 27, 2026一株当たり利益（EPS）-34.63グロス・マージン100.00%純利益率-552.46%有利子負債／自己資本比率0%7BG の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/04 20:44終値2026/08/03 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Oncoinvent ASA 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Geir HolomDNB Carnegie
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr58m net loss in 3 years). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (kr28m revenue, or US$2.9m). Market cap is less than US$100m (€26.5m market cap, or US$30.2m).
お知らせ • Jun 19Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of RadspherinOncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine.
Board Change • May 20No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Mar 20Oncoinvent Secures New Patent Expanding Protection for RadspherinOncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.
お知らせ • Feb 18Oncoinvent to Present Positive 24-Month Follow-Up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026Oncoinvent announced that it will present final 24-month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum-sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes. The poster presentation, titled 'Safety and efficacy results from a phase 1 study of intraperitoneal alpha-EMitting radium-224 labelled microparticles after cytoreductive surgery, will share final 24-month data from the Phase 1 study detailing: 21 patients enrolled across dose levels with a favourable safety profile and no dose-limiting toxicities observed; No grade 3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence.
お知らせ • Jan 13Oncoinvent ASA Announces Appointment of Ramzi Amri as CEO, Effective January 2026Oncoinvent ASA announced the appointment of Ramzi Amri as the new CEO of the Company as of January 2026.
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr58m net loss in 3 years). Share price has been volatile over the past 3 months (8.1% average weekly change). Revenue is less than US$5m (kr28m revenue, or US$2.9m). Market cap is less than US$100m (€26.5m market cap, or US$30.2m).
お知らせ • Jun 19Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of RadspherinOncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine.
Board Change • May 20No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Mar 20Oncoinvent Secures New Patent Expanding Protection for RadspherinOncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide.
お知らせ • Feb 18Oncoinvent to Present Positive 24-Month Follow-Up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026Oncoinvent announced that it will present final 24-month results from its RAD-18-001 Phase 1 study of Radspherin after cytoreductive surgery in patients with platinum-sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026. Radspherin is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes. The poster presentation, titled 'Safety and efficacy results from a phase 1 study of intraperitoneal alpha-EMitting radium-224 labelled microparticles after cytoreductive surgery, will share final 24-month data from the Phase 1 study detailing: 21 patients enrolled across dose levels with a favourable safety profile and no dose-limiting toxicities observed; No grade 3 adverse events considered related to Radspherin; Recommended dose selected at 7 MBq following dose escalation; Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence.
お知らせ • Jan 13Oncoinvent ASA Announces Appointment of Ramzi Amri as CEO, Effective January 2026Oncoinvent ASA announced the appointment of Ramzi Amri as the new CEO of the Company as of January 2026.
Board Change • Dec 30No independent directorsThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 8 new directors. 3 experienced directors. No highly experienced directors. No independent directors (8 non-independent directors). Director Orlando Oliveira is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Dec 03Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million.Oncoinvent ASA has completed a Follow-on Equity Offering in the amount of NOK 130 million. Security Name: Shares Security Type: Common Stock Securities Offered: 260,000,000 Price\Range: NOK 0.5 Transaction Features: Rights Offering
お知らせ • Nov 01Oncoinvent ASA Announces CFO Changes, Effective on or Around January 15, 2025Oncoinvent ASA announced the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January. Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. Dr. Amri joins Oncoinvent from Galapagos NV, where he most recently served as Vice President and Head of Development Strategy & Execution. He brings broad international experience through leadership positions in strategy, operations, and corporate transformation across the life sciences and healthcare industries. Dr. Amri also brings seven years of management consulting experience from McKinsey & Company, advising global pharma and biotech clients, as well as financial institutions and private-equity-backed businesses, on growth, M&A, and organizational transformation. Dr. Amri holds an M.D. and a Ph.D. from the University of Amsterdam. He conducted his Ph.D. research and completed a postdoctoral fellowship in surgical oncology and epidemiology at Harvard Medical School and Massachusetts General Hospital, where he initiated and led a research program in colorectal cancer.
